Mergers & Acquisitions ·
Ligand Pharmaceuticals reported second quarter 2026 GAAP net income of $48.5 million ($2.22 diluted share), up from…
LGNDLigand Pharmaceuticals Inc
Ligand Pharmaceuticals reported second quarter 2026 GAAP net income of $48.5 million ($2.22 diluted share), up from $4.8 million in the prior year, driven by a 32% increase in royalty revenue to $48.0 million and total revenues of $63.7 million. The company completed a $700 million convertible senior notes offering at 0% interest and closed its acquisition of XOMA Royalty on July 14, 2026, adding over 120 assets including Roche’s VABYSMO and Servier’s OJEMDA. Management raised the low end of full-year adjusted EPS guidance to $9.00 from $8.50 while reaffirming total revenue expectations of $270 million to $310 million. Ligand Pharmaceuticals operates in the biopharmaceutical sector, functioning as a royalty aggregator that finances and advances late-stage clinical development programs.